Updated:
GHO Capital
GHO Capital, launched in 2014 by former 3i healthcare investors, is a London-based private equity firm focused exclusively on European healthcare buyouts.
GHO Capital
GHO Capital was founded in 2014 by three former 3i healthcare investors — Alan MacKay, Andrea Ponti and Mike Mortimer — who left the listed UK private equity firm to build a specialist vehicle concentrated entirely on healthcare. The trio identified a supply-demand gap: a wave of founder-owned European healthcare businesses approaching succession, and too few dedicated buyers who understood medical reimbursement codes, regulatory pathways and clinical-audit culture. GHO raised its debut fund in 2015, its second in 2019, and its third fund by 2023, each meaningfully larger than the last, per the firm's official communications. The firm executes control buyouts and complex carve-outs across three verticals — pharmaceuticals, medical devices, and healthcare services — with particular emphasis on businesses serving aging demographics in Northern Europe. GHO has deployed into clinical research organizations, specialty pharma manufacturing, and dental care platforms. Confirmed past and current portfolio companies include Ardena, a Dutch CDMO, and Sterling Pharma Solutions, a UK-based API manufacturer. The firm operates bilaterally, often negotiating directly with founders over 12–18 months rather than competing in broad auctions. Geography prioritizes the UK, Ireland, DACH region, Nordics and Benelux. In September 2023, GHO closed its third fund, GHO Capital III, at €2.3 billion, exceeding its €2 billion target (per the firm, September 2023). The raise tripled the €750 million secured for Fund II in 2019 and drew commitments from sovereign wealth funds, public pension plans and endowments across North America, Europe and the Middle East. The team operates from London with coverage across Western Europe. GHO has not launched adjacent credit or venture vehicles, maintaining a single-product focus unusual among mid-market peers who typically bolt on growth or credit strategies. The firm's structural differentiator is the intensity of its vertical focus. GHO does not invest in technology for technology's sake — its partners carry Ph.D.-level scientific training, and its operating partners are former pharma executives and hospital-group CEOs who sit on portfolio boards. This clinical-operating DNA means portfolio companies often share suppliers, regulators and even management talent across the portfolio, creating a de facto healthcare ecosystem inside a single GP. The succession model is also distinct: GHO targets founder transitions where the seller remains as a minority shareholder and clinical guardian for a multi-year earn-out, aligning incentives in a regulated industry where patient outcomes are the ultimate reputational risk.
General information
Firm type
Private Equity
Year founded
2014
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Principals
Alan MacKay
Managing Partner
Andrea Ponti
Managing Partner
Mike Mortimer
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at GHO Capital?
Day-to-day decisions sit with the three managing partners — Alan MacKay, Andrea Ponti and Mike Mortimer — all of whom worked together in 3i's healthcare team before founding GHO in 2014. The firm operates a flat investment committee where all three carry equal weight, supported by sector-specific partners covering pharma services, medtech and healthcare providers. No single partner can unilaterally commit capital above a pre-agreed threshold, per the firm's public governance materials.
Does GHO Capital invest outside Europe?
GHO's mandate is exclusively European, but its portfolio companies often generate substantial revenue in North America and Asia. The firm invests in businesses headquartered in Western Europe — principally the UK, Ireland, DACH, Nordics and Benelux — and then uses its capital to accelerate international expansion. It has not opened non-European offices and does not do direct investments in North American or Asian target companies.
What is GHO Capital's position on co-investments?
GHO actively offers co-investment rights to its limited partners on larger transactions, particularly those exceeding €200 million in enterprise value, per LP communications. The firm has not historically syndicated co-invest to non-LP outside capital, preferring to deepen relationships with existing institutional backers rather than broaden the investor base.
How does GHO Capital source its deals?
GHO relies on a proprietary origination model rather than auction processes. The operating partner network — composed of former pharma executives, hospital CEOs and regulatory experts — identifies founder-owned businesses approaching succession before they formally come to market. The firm then negotiates bilaterally over extended periods, often 12–18 months, structuring transactions where the founder remains a minority shareholder during a defined earn-out period.
Which sectors does GHO Capital avoid?
GHO avoids pure-play health tech and software-as-a-medical-device businesses where valuations are driven by recurring-revenue multiples rather than clinical outcomes — the firm has publicly stated it invests in 'healthcare, not health tech.' It also avoids public-to-private transactions in regulated payor markets like the NHS where political risk is difficult to underwrite, and stays away from Phase I biotech assets that require binary FDA approval bets.
Does GHO Capital manage any credit or venture vehicles?
No. GHO maintains a single-product structure — control buyouts in its flagship closed-end funds. It has not launched complementary credit strategies, continuation vehicles, or early-stage healthcare venture funds, which distinguishes it from mid-market peers like Archimed or Gilde Healthcare that operate multi-strategy platforms.
How is GHO Capital's fund performance measured publicly?
GHO does not publicly disclose fund-level IRRs or MOICs. Fund I has fully exited several assets, per the firm's investor letters, but discrete performance data is limited to LP reports. The €2.3 billion close of Fund III in 2023 — triple the size of Fund II — serves as the strongest public signal of re-up rates and LP satisfaction.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: